• Promethazine HCl in Macrophage Research

  2026-08-14

  Promethazine HCl gives researchers a practical way to connect H1-receptor blockade with macrophage ROS, lysosomal activity, and autophagy assays. This workflow separates host-directed antibacterial effects from direct bacterial toxicity while supporting inflammation research and GPCR/G protein signaling studies.

• Paroxetine Mesylate Research Workflows

  2026-08-13

  Paroxetine Mesylate supports parallel neuropharmacology, enzyme-interaction, kinase, and colorectal cancer workflows rather than a single-target experiment. This guide translates its reported SERT, CYP2D6, GRK2, MET, and ERBB3 activities into practical assay design, controls, and troubleshooting strategies.

• Coumestrol, PMAIP1, and Ferroptosis in RA-FLS

  2026-08-13

  A 2026 study identifies a TRIM3–PMAIP1 regulatory axis through which Coumestrol promotes ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes. Its integrated use of proliferation, inflammatory, mitochondrial, iron, and gene-silencing assays provides a mechanistic framework for studying abnormal synovial-cell behavior.

• Dacomitinib: Irreversible Pan-HER Research Guide

  2026-08-12

  Dacomitinib, also called PF-00299804, is an irreversible ErbB-family kinase inhibitor with nanomolar activity against EGFR, HER2, and HER4. Its strongest evidence supports EGFR-mutant non-small-cell lung carcinoma treatment research and HER2-amplified breast cancer research, while ferroptosis connections remain a hypothesis rather than a demonstrated direct action.

• 17-AAG (Tanespimycin): HSP90 Research Guide

  2026-08-12

  17-AAG, also called Tanespimycin, is a synthetic geldanamycin analogue used to investigate HSP90 chaperone inhibition in cancer. Its reported activity includes low-nanomolar HSP90 inhibition, degradation of oncogenic client proteins, cytotoxicity in cancer-cell assays, and tumor-growth suppression in xenograft models.

• Ionomycin calcium salt for Reliable Cell Assays

  2026-08-11

  This scenario-driven guide explains how Ionomycin calcium salt, SKU B5165, can help researchers control intracellular Ca2+ signaling while separating calcium responses from metabolic or apoptotic assay artifacts. It covers experimental design, protocol handling, interpretation, and practical vendor-selection criteria for cell viability, proliferation, and cytotoxicity workflows.

• Liproxstatin-1 in Ferroptosis Assay Design

  2026-08-11

  Liproxstatin-1 is a ferroptosis inhibitor that helps distinguish lipid peroxidation-driven cell death from nonspecific oxidative injury. This guide translates salivary-gland findings into a rigorous, disease-aware assay strategy for ferroptosis research.

• Tricine-SDS-PAGE Gel Preparation Kit Guide

  2026-08-10

  The Tricine-SDS-PAGE Gel Preparation Kit is designed for high-resolution protein electrophoresis of low-molecular-weight proteins and peptides, especially targets in the 1–10 kDa range. It is intended for research workflows rather than diagnostic or medical use, and its SDS-free gels can support both denaturing and non-denaturing electrophoresis when the sample and running conditions are selected accordingly.

• Paroxetine in Colon Cancer: MET–ERBB3 Evidence

  2026-08-09

  The reference study investigated paroxetine as a repurposing candidate in colorectal cancer and connected its antiproliferative effects with MET and ERBB3 signaling. Across colon cancer cell, spheroid, colony-formation, and xenograft models, the compound reduced growth and promoted apoptosis, while the mechanistic evidence pointed to coordinated changes in AKT, ERK, p38, JNK, and caspase-3 pathways.

• How DNA Frameworks Improve Enzymatic DNA Synthesis

  2026-08-08

  The reference study introduces tetrahedral DNA nanostructures as an ordered primer interface for enzymatic oligonucleotide synthesis. By improving primer orientation and enzyme accessibility, the framework increased catalytic performance, reduced deletion errors, and enabled a 60-nucleotide DNA information-storage fragment with a reported 96.82% stepwise yield.

• METTL17, Mitochondrial Translation, and CRC Ferroptosis

  2026-08-07

  The reference study identifies METTL17 as a mitochondrial RNA-methylation regulator that helps colorectal cancer cells preserve mitochondrial translation and resist ferroptosis. Its combination of cellular, molecular, and in vivo evidence positions METTL17 as a potential vulnerability for ferroptosis-based colorectal cancer research, while also defining important limits for translation beyond the tested models.

• Patient-Derived 3D Spheroids Advance Prostate Cancer Modelin

  2026-08-07

  This study establishes and characterizes three-dimensional spheroid cultures derived from radical prostatectomy tissue, providing a versatile in vitro model for organ-confined prostate cancer. The approach enables long-term viability, molecular profiling, and drug response testing, offering a significant step forward for translational cancer research.

• nor-Binaltorphimine Dihydrochloride: Precision Tools for Dec

  2026-08-06

  Discover how nor-Binaltorphimine dihydrochloride, a potent κ-opioid receptor antagonist, enables advanced mechanistic studies of opioid-induced pain and tolerance. This in-depth guide offers fresh insights into neural circuit dissection, assay design, and translational research.

• Afatinib (BIBW 2992): Irreversible ErbB Inhibitor for Cancer

  2026-08-06

  Afatinib is a potent irreversible inhibitor of EGFR, HER2, and HER4 kinases, widely used in cancer biology research. Its covalent binding mechanism allows robust inhibition of ErbB signaling, even in models with resistance mutations. This article details Afatinib's molecular action, benchmarks, and best-practice integration for advanced tumor models.

• METTL17 Modulates Ferroptosis via Mitochondrial Translation

  2026-08-05

  This study identifies METTL17 as a pivotal regulator of ferroptosis resistance and tumorigenesis in colorectal cancer (CRC) by modulating mitochondrial RNA methylation and translation. The findings provide new mechanistic insight into mitochondrial-mediated cell death and highlight METTL17 as a potential therapeutic target to sensitize CRC cells to ferroptosis-based interventions.

7666 records 2/512 page Previous Next 12345 下5页 Last page